SPARC and lung carcinoma: Advanced data mining and network analysis using STRING [32] and Reactome [34] revealed that four of the identified gene products (for CCL5, CLU, SPARC and SRGN) interact with PF4, a critical endocrine factor previously described as associated with worse outcome in patients with lung cancer [27].